Tetrahydroxycurcumin (200 mg/kg‐1 orally administered for 3 and 20 weeks) was found to reduce the phosphorylated inhibitor kappaB alpha, cyclin D1, and 8‐hydroxy‐2‐deoxy‐guanosine in a rat model of gastric cancer caused by N‐methyl‐N‐nitrosourea and saturated sodium chloride (Koh et al. 2021). The gene discussed is CCND1; the disease is gastric cancer.